scholarly journals L-Glutamate-induced swelling of cultured astrocytes: Involvement of high-affinity glutamate uptake systems

1992 ◽  
Vol 58 ◽  
pp. 248
Author(s):  
Tadashi Ishibashi ◽  
Yutaka Koyama ◽  
Akemichi Baba
2022 ◽  
Vol 15 ◽  
Author(s):  
Pauline Beckers ◽  
Olaya Lara ◽  
Ines Belo do Nascimento ◽  
Nathalie Desmet ◽  
Ann Massie ◽  
...  

Disruption of the glutamatergic homeostasis is commonly observed in neurological diseases and has been frequently correlated with the altered expression and/or function of astrocytic high-affinity glutamate transporters. There is, however, a growing interest for the role of the cystine-glutamate exchanger system xc– in controlling glutamate transmission. This exchanger is predominantly expressed in glial cells, especially in microglia and astrocytes, and its dysregulation has been documented in diverse neurological conditions. While most studies have focused on measuring the expression of its specific subunit xCT by RT-qPCR or by Western blotting, the activity of this exchanger in tissue samples remains poorly examined. Indeed, the reported use of sulfur- and carbon-radiolabeled cystine in uptake assays shows several drawbacks related to its short radioactive half-life and its relatively high cost. We here report on the elaborate validation of a method using tritiated glutamate as a substrate for the reversed transport mediated by system xc–. The uptake assay was validated in primary cultured astrocytes, in transfected cells as well as in crude synaptosomes obtained from fresh nervous tissue samples. Working in buffers containing defined concentrations of Na+, allowed us to differentiate the glutamate uptake supported by system xc– or by high-affinity glutamate transporters, as confirmed by using selective pharmacological inhibitors. The specificity was further demonstrated in primary astrocyte cultures from transgenic mice lacking xCT or in cell lines where xCT expression was genetically induced or reduced. As such, this assay appears to be a robust and cost-efficient solution to investigate the activity of this exchanger in physiological and pathological conditions. It also provides a reliable tool for the screening and characterization of new system xc– inhibitors which have been frequently cited as valuable drugs for nervous disorders and cancer.


2000 ◽  
Vol 871 (2) ◽  
pp. 175-180 ◽  
Author(s):  
R.D Azbill ◽  
X Mu ◽  
J.E Springer

Talanta ◽  
2015 ◽  
Vol 135 ◽  
pp. 67-74 ◽  
Author(s):  
O. Soldatkin ◽  
A. Nazarova ◽  
N. Krisanova ◽  
A. Borуsov ◽  
D. Kucherenko ◽  
...  

1996 ◽  
Vol 28 (1-3) ◽  
pp. 127-133 ◽  
Author(s):  
José G. Ortiz ◽  
Olga Claudio ◽  
Glysette Santiago ◽  
Mayra L. Cordero ◽  
Jennifer Nieves

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Zenji Kawakami ◽  
Yuji Omiya ◽  
Kazushige Mizoguchi

The traditional Japanese Kampo medicine yokukansan (YKS) is effective for behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease. As the pharmacological mechanisms, YKS is known to protect astrocytes from thiamine-deficiency (TD)-induced decreased glutamate (Glu) uptake and neuron model cells (PC 12 cells) from Glu-induced death. Yokukansankachimpihange (YKSCH) is an alternative formula to YKS, in which Citrus unshiu peel and Pinellia tuber are added to the YKS components, and is sometimes used to treat BPSD, but its pharmacological properties remain unknown. This study aims to investigate the cellular pharmacological effects of YKS and YKSCH on glutamatergic pathways, compare their efficacy, and determine the differences and similarities in the activities between these formulations. First, we examined the effects of YKS and YKSCH on Glu uptake by cultured astrocytes under TD conditions. We observed significant ameliorative effects of YKS and YKSCH on the TD-induced decrease in Glu uptake, with a 50% effective dose of 8.9 ± 1.8 μg/mL and 45.3 ± 9.2 μg/mL, respectively. Second, using cultured PC12 cells as a model for neurons, we examined the effects of YKS and YKSCH on Glu-induced cell death. We observed that YKS and YKSCH had significant inhibitory effects on Glu-induced cell death, with a 30% effective dose of 51.4 ± 20.8 μg/mL and 49.2 ± 11.0 μg/mL, respectively. Thus, while YKSCH was less effective than YKS in ameliorating the TD-induced decrease in Glu uptake by astrocytes, the two drugs showed similar inhibitory effects on Glu-induced PC12 cell death. These findings are important for understanding the differences and similarities in pharmacological actions between these drugs.


Sign in / Sign up

Export Citation Format

Share Document